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DETERMINATION OF HEPARIN IN BLOOD
C. H. Hemket nnd S. Bdguin
Haemctas's and Thrombosis 1990, Edited by D Kebcr. Mediciroki rogledi, Ljublim 1990'
INTRODUCTION
Probably the mostimportant antithrombotic drug in-use atthe moment is heparin (1-10)'
Actuaflf the annual iale in the Netherlands is 6.1010 U, that is 2000 U per head of the
poprrlato.r. Its administration by injection and the fact that the prescribing doctors are
well aware of the inherent risk of bleeding (11) make that it is not likely to be used
inJvertently. The consumption in the Netherlands is probably the minimum that can
be used in any medical community that takes the prevention and treatrnent of thrombosis
seriously because especialty in this country the use of the only serious alternative 
- i'e'
oral unticougulatio.- is',reiy well organized and hence very common (12'L3).
In recent years we have witnessed the advent of low molecular weight heparins
(LlvMH), [h"." u." indications that they may be more convenient drugs then unfrac-
tionatedheparin (uFH) is Ga-23).This piomises that heparin usage will still increase- In
fact the discussion that is going o., o., iMWH ulready seems to bring about a rise in the
use of UFH.
This situation makes that the question of how to determine heparin in the plasma of a
patient becomes more and moie urgent. Logically another question should precede the
questionof kozo todetermineheparin,and thatis zolry to determine heparin' Is itnecessary
to determine heparin levels (or a related parameter) or will giving standard doses do the
job? That fundamental question can be answered only from controlled-clinical trials and
fo. su.h trials an adeq,rate heparin test must be available. This is a circular argument'
Therefore the question of what makes a good heparin test may well be the one to start
with.
CURRENT TYPES OF HEPARIN TESTS
All current determinations of heparin are based on its influence on the blood coagulation
process i.e. its enhancing effeit on the inactivation of activated clotting factors by
antithrombin III (AT III). ierreral other actions of heparin have been described however'
It binds to the vessel wall(u-27),influence.s fibrinolysis (2s-32), causes the release of
lipoprotein lipase (33-38) etc. we keep thinking that its main therapeutic action is on
Uiooa coag,rtition for a simple reason: vitamin K antagonists also have a large sPectrum
of actions apart from that on coagulation. Yet coagulation is the only one that it has in
common with heparin. It seems more likely then not that it is indeed this common
denominator that has the antithrombotic effect. Until proof of the contrary we therefore
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think that a test of the coagulation system is the most adequate to reflect the therapeutic
action of heparin.
What are the current coagulation based tests of heparin activity? They come in several
kinds:
1. Thrombin time (I-D @942). These tests are based upon the clotting of plasma by a
fixed amount of added thrombin.
2. Activated partial thromboplastin time (aPTT) (41-50). Based upon starting coagula-
tion in the patient's plasma via the intrinsic pathway.
3. Heptest (39,51,,52). Aclotl:rng time started with activated factor X among other things.
4. Anti-thrombin tests (39,53-59,62). An amount of thrombin is added and the test
measures the amount that remains active after a fixed incubation time.
5. Anti-factor Xa tests (39,55-62). Like 4, but now with factor Xa rather then with
thrombin.
6. Neutralisation tests (63,64).
Under 6 we group a number of more specific and more precise tests that are not in toutine
use, often because they are relatively time consuming or require techniques not readily
available in the clinical laboratory. The neutralization tests, based upon titration of the
heparin in the sample with a heparin neutraliser such as protamine are mainly used for
determining precisely the high heparin concentrations met in extracorporal circulation.
These will not be discussed further because we focus on tests for heparin treatment and
prevention here.
Tests 1, 2 and 3 are clotting tests; 4 and 5 are spechophotometric tests based on the use
of thrombin- or factor Xa-specific chromogenic substrates. Tests 1 and 4 measure the
anti-thrombin effect tests 3 and 5 the anti-factor Xa effect. The way in which heparin
influences the aPTT has until recently remained relatively unclear. Especially the reason
why the aPTT is sensitive to heparin whereas the PT (Quick-time) is not, remained
obscure. We demonstrated that the aPTT is primarily dependent upon the time necessary
for trace amounts of thrombin to activate so much factor VIII that a burst of thrombin
formation ensues (65,66). This positive feedback effect of thrombin on its own formation
is the main feature of the kinetics of the aPTT. Heparin prolongs the aPTT by enhancing
the action of AT III on the trace amounts of thrombin that act as a feedback activator.
Once the burst of massive thrombin generation occurs coagulation follows immediately,
largely independent of the amount of thrombin that is formed- In the PT the feedback
activation of factor VIII does not play a role, as would be expected, but, possibly because
of the large excess of factor Xa and the availability of factor V (not bound to von
Willebrand factor), the feedback of thrombin on factor V does not play a role either.
Heparin will decrease the peak amount of thrombin formed in both aPTT and PT. That
the PT is insensitive to heparin illustrates the fact that decreasing the peakamount does
not influence the clotting time (see later).
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The Heptest is a kind of aPTT that is started by he addition of activated factor X to the
sample. If factor Xa is rapidly broken down, as in the presence of heparin (either UFH
or t'UWf1 this test wili prolong. On the other hand it also is sensitive to thrombin
inactivation. The first effect is more important though and the Heptest therefore may be
regarded as "the poor man's anti Xa" (64)-
For several years it has been thought that the antithrombin action of heparin was
responsible ior bleeding whereas the anti-Xa action was thought to reflect antithrom-
botic power (6 7-69).Moie tecent research very much doubts whether this is the case (15
70-Z1,i.In fact it could be demonstrated that UFH in the concentration range used for
prophytaxis or treatment of thrombosis has only a very small effect on the conversion
vetocity of prothrombin in clotting plasma (65,56,72,73) whl\e its antithrombotic action
is not quesioned. On the other hand a trial on a LMWH that had a high anti-Xa action
had to te stopped because of the many bleeding complications in the treated group (21)-
PLATELETS AND HEPARTN
means that important amounts of PF4 may be shed so that between 0 and 0'4U/ml of
heparin will escape attentionl Collecting blood on a platelet inhibitor is a partial solution
to this problem. Unless this is done any exact heparin determination is illusory and 0.18
+/- O.Oi U/ml will be neutralised in the sample (93). Even when collecting on platelet
inhibitor the difference between heparin in a patien(s sample and spiked heparin
remains, be it to a lesser extent (94,95).
The very fact that platelet activation is an important event in haemostasis and thrombosis
makes that the PF4 susceptibility of a heparin will be one of the factors that determine
its in vivo action. tf thrombin generation in PRP is triggered by small amounts of tissue
thromboplastin, a test system is obtained that is one step nearer to the in vivo situation
than testi in platelet poor plasma (PPP) are. Under these circumstances a burst of
thrombin formation is observed about five minutes after starting the reaction. In the
presence of UFH this burst is dosedependently postponed but the amount of thrombin
iormed is not diminished. This is because trace amounts of thrombin that are generated
during the lag-phase activate the platelets. Once the platelets are activated they provide
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procoagulant phospholipids and factor V which allow a massive increase of thrombin
formation. The sifuation is completely comparable to the feedback activation of factor
VIII discussed above but even more oubpoken. The amount of thrombin available
during the lagphase is less in the presence of heparin and hence the lagphase will
prolong. Once the platelets are activated they shed so much PF4 that the heparin is
neutralized and the thrombin then formed is not or hardly inhibited at heparin con-
centrations up to 0.4 U/ml. None of the current tests takes this effect into accounl This
is the more regrettable because here an important difference between UFH and LMWH
shows up. LMW Heparins are much less susceptible to PF4 inactivation then UFH is and
each of them to a different extend (96,97).
HOW TO CHOOSE A HEPARIN TEST?
For a good heparin test there is one minimal requirement it should indicate the amount
of active material in the circulation of the patient. Indeed there need not even be a
relation between the property measured and the property that carries the pharmacologi-
cal effect, a correlation will do. If heparins would strongly adsorb at a convenient
wavelength or carry detectable radioactivity, then these properties could be used for
measuring heparin concentrations in plasma. Even if the molecules that carry the signal
would not be the same as those carrying the pharmacological effect.
On the other hand one dreams of the ideal test, which does not inform us about the
amount of material in the blood but about the effect of that material on the relevant
properties of the blood. In other words: the test that would not be a concentration-in-
dicator but a true model of the therapeutic efficacy.
It looks as if, in the heparin field, we do have an acceptable test of the first type, whereas
we are far from having one of the second type. This is all the more regrettable because
heparins are notoriously heterogeneous. This makes that any property that we measure
and that has not been proven to indicate therapeutic efficacy directly, may fool us as
soon as the proportion of the indicator property to the effector property changes.
There are at this moment good reasons to believe that anti-factor Xa activity is an
acceptable indicator for concentrations of circulating heparin. In many clinical studies it
has been shown to correlate with the effect, at least when LMWHs are compared and
within the rather broad limits that are set by clinical dose finding studies (98,104). From
animal studies one has good grounds to doubt wether it also holds for a purely anti-factor
Xa heparin like the Choay pentasaccharide (105).
Particulary interesting is the study of Cadroy in baboons that presents a model of the
arterial platelet thrombus and that compares the dose-effect curves of UFH and of the
very low molecular weight heparin CY222in that model (106).The results of this shrdy
have been interpreted as to indicate the practical usefulness of the anti-thrombin test
(107). This seems indeed a sound conclusion. Concluding however on basis of these tests
that anti-thrombin measurements or even weisht would be less usefull seems Drecocious.
98
/DETERMINATION OF HEPARIN IN BLOOD
The matter can be conveniently discussed in terms of IC50 concentrations (108). When
anti-factor Xa activity is used to compare the lC5{l',s of both heparins, then they aPPear
to be much closer then when they are expressed in terms of either weight or anti-throm-
bin activity (table 1). This in the core of reasoning of ref- (107)-
Table 1- Comparimn of lC50 ulucs of tzn difioent hepains.
CI?ft2 R.tio
ICso (Fglntl-)
AntiXa (U/mL)
Anti IIa(U/mL)
High affinity maL(%)
IC5) tlA.mat (mg/ml-)
Decay constant at IC5)
Factor Xa
Factor IIa
This certainly prooves the practicability of the anti-factor Xa activity test. Does it however
settle the argument in disfavour of either weight or anti-thrombin activity tests? Let us
discuss weight first- What substance should be weighed? Obviously the active substance.
Even though it has been described that non-AT III binding heparins contribute to the
antithrombotic activity (109), one is rather tempted to think that the amount of AT III
binding material is the important thing. We determined,by fluorescence-titration of pure
AT III the percentage high affinily material in UFH and CY 222.If the IC50s are calculated
in weight of AT III binding material, it appears that the difference between UFH and
CY?22 is mainly due to a difference in content of high affinity material (table 1). Thus
the apparently strong case against weight as a basis of comparison seems to weeken.
Below we will argue that also the anti-thrombin activity may not be as easily dismissed
as would be thought on basis of a quick interpretation of Cadroy's results.
Nevertheless one must admit that the presently available anti-thrombin tests are less
sensitive then the anti-test, especially in the case of LMWHs. It remains an interesting
question whether its sensitivity could be increased by rigorous prevention of platelet
activation in the samples.
The aPTT test measures principally the effect of heparin on the feedback activation of
factor VIII by thrombin and on factor IXa inactivation during the lag phase of thrombin
formation (65,66,110)- lt is an indirect test of antithrombin action that is more sensitive
then the direct test is because it takes advantage of the amplifying effect of the feedback
mechanism. The main drawbackis the large individual variation. it has been shown that
spiking individual patient plasmas with the same amount of heparin results in very
different prolongation ratios of the aPTT- This is probably due to the fact that the test is
sensitive to the levels of all clotting factors, all heparin binding proteins and also to
pathological inhibitors (111-116). Also different rypes of the test (as to contact activator
used and phospholipid preparation) will give different outcomes.
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We conclude that the anti-factor Xa activity test seems to fulfill the minimal requirements
for a heparin determination. In comparing it to other tests, it must be said in its favour,
that it seems to be more sensitive and less subject to inter patient variation then the
trombin time and the aPTT, especially with LMWHs. The Heptest seems to hold an
intermediary position here.
HOW TO FIND A MODEL FOR CLINICAL EFFICACY?
After having argued that the anti-factor Xa activity test at this moment is probably the
best available practical shortcut to heparin measurement, we will now show that it can
by no means be accepted as a model for clinical efficacy. This may seem a srrperfluous
remark because it never has been claimed that it would be. It is well known however
that any test that is in general use gets a respectability of its own that might make it slip
stealthily in the position of the accepted standard (1 17).
We found a method that enabled us to measure the velocity of prothrombin conversion
in clotting plasma, independant of the simultaneous thrombin inactivation. Surprisingly
CY222 and other substances that show a high conventional anti-factor Xa activity, do
not show a parallel inhibition of prothrombin conversion in the extrinsic system. This is
an unexpected result because the only physiological effect of factor Xa is prothrombin
conversion. The reason is that factor Xa is produced during coagulation in such excess
that it can be inhibited quite markedly before any effect on prothrombinase activity can
be observed. In the inhinsic system heparin does inhibit prothrombin conversion, but
this must be athibuted to a secondary effect on the feedback activation of factor VIII by
thrombin and to inhibition of factoi lXa (64,65,710).
The main effect of heparins, be it fractionated or unfractionated, is inactivation of
thrombin. The only exception are very low molecular weight products like pentasac-
charide and certain subfractions of the usual LMWHs (64,96,97).
If indeed anti-thrombin activity is the main action, then why do the IC50s of that property
not compare? (table 1). The reason is probably that the anti-thrombin activity and the
anti-factor Xa activity as they are routinely measured bear only a distant relationship to
the same properties in clotting plasma. In the study of Cadroy the anti-thrombin activity
was measured by the aPTT and by the TT. These can not be accepted as exact quantitative
estimations of the anti-thrombin effect (see above). Neither is the anti-factor Xa activiby
as measured routinely a good indicator of what happens to factor Xa in plasma. It has
been shown that the decay of factor Xa in plasma varies both with the species from which
the factor Xa is prepared and with the concentration of Ca**; moreover these variations
are not the same with different types of heparin. It therefore will make an enormous
difference whether bovine factor Xa decay is measured in the absence of Ca* *, as in the
anti-Xa test, or human Xa in the presence of Ca+ +, as in vivo.
We measured the specific decay constants of standard UFH and of CY222 in human
plasma with human factor Xa and at physiological Ca** concentration. Then we calcu-
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lated what the effect of the IC50s of Cadroy would be in PPP on the decay of thrombin
and factor Xa. We see that the almost tenfolfd difference between anti-factor Xa activity
and anti-thrombin activity of the original data tend to diminish to a bare twofolfd (table
1). We are conscious that we are applying data from human plasma to the in vivo
situation in baboons, but it is the best approximation that we can offer for the moment.
THE SEARCH FOR IDEAL TEST
We must conclude that the ideal test for anticoagulant treatment does not yet exist. We
therefore should try and make one. Such a test should meet a number of stiff demands,
it should:
a. Be equally sensitive to comparable therapeutic levels of oral anticbagulation, and of
treatment by heparin or heparinlike drugs.
b. Be sensitive to the inhibition of factor Xa (or any other clotting factor (notably factor
Xa)) only insofar as this factor influences thrombin generation.
c. Be either not hampered by platelet acfivation (PPPtest) or take physiological platelet
activation into account (PRPtest)-
There is only one procedure that, as far as we can see, approaches these requirements.
It has been in practical use for many decades and is often tacitly assumed to be the golden
standard for effects on the coagulation system. We mean the thrombin generation test
GGT). It is indeed influenced by all anticoagulation procedures. It reflects inhibition of
individual clotting factors, but not proportionally to their percentual variation, except
for prothromb\n (117).It can be carried out equally well in PRP as in PPP.
The thrombin generation curve of course has a mayor drawback: it takes an experienced
laboratory, much time and a lot of reagent. This makes that until now it has practically
been used for research purposes only.
In order to develop a routine test on this basis one should first decide what type of value
one wants to measure. A classical TGT shows a number of different features. One can
measure the tagtime of thrombin formation, the peak value of thrombin obtained or the
surface under the curve. The lagtime is equivalent to a clotting time, because clotting is
invariably seen at the beginning of the thrombin burst. In our experience the surface
and the peakvalue correlate strongly. There is a theoretical argument to favour the
surface under the TGT as an essential variable: thrombin is an enzyme. One nanomolar
for ten minutes wil l  in principle have the same effect as ten nanomolar for one minute.
This means that the product of time and thrombin concentration is important. which is
equivalent to the surface under the curve (118). As the next section will show. we
developed a method that directly renders this surface from an easily automated test.
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A CANDIDATE: THE THROMBIN POTENTIAL AND HOW TO
MEASURE M
As discussed abovgit is a common property of all antithrombotic drugs that they
diminish the amount of thrombin generated in clotting plasma, either because there are
less clotting factors present (oral anticoagulation) or because the thrombin formed
disappears faster (heparins etc.). Whether heparins also inhibit (the formation of)
prothrombinase and inhibit thrombin formation also in that way is of no importance for
the present purpose. If they do this effect is also measured by the procedure that we are
going to discuss. Under antithrombotic treatment as described above the form of the
thrombin generation cr.rwe changes in one or more of the following respects: it starts later,
i.e. the lagphase before explosive tfuombin formation occurs is longer, the peak is lower or
the decay is faster so that the thrombin present is inactivated earlier. It has beEn shown that
a lower generation (oral anticoagulation) as well as a faster decay (heparin heaEnent) cause
efficacious antithrombotic treahnenl Both result in a smaller surface under the thrombin
generation cuwe. This surface we define as the endogenous ttuombin potential @TP) of the
plasma. We here present the outlines of a method to determine the ETP and we think that
the ETP thus measured can, among other thinp, serve to measure the effect of any known
anticoagulant drug: hepariru and heparin likes, himdin and oral anticoagulation.
In the assay that we propose a test sample of blood, platelet rich plasma, platelet poor
plasma or defibrinated plasma is added to a solution containing a trigger of the coagula-
tion process, a source of Ca++ ions, a preparation of a natural antithrombin and a
substrate of thrombin. The natural antithrombin may be antithrombin III or heparin
cofactor II or both. They serve the purpose of rendering the test less sensitive to variations
in the concentration of these inhibitors in the test sample and to minimise the side
reaction with other antithrombins such as a2Macroglobulin. By selecting either ATIII
or HCII the test can be made specifically sensitive to drugs of the heparin, resp. of the
dermatan sulfate type. It is not even excluded that under certain circumstances it may
not be absolutely necessary to add exha inhibitors to the reaction medium. What is
essential to the present test is that a subshate is used that is not exhausted during the
lifetime of the thrombin that generates and disappears in the clotting plasma. The
mixhrre with the test sample is incubated during a specified time under specified
conditions. Then the amount of thrombin substrate is read directly or, in opaque
solutions the reaction is stopped by adding a thrombin inhibitor and the mixture is
treated, e-g. by cenhifugation in order to allow determination of the amount oi product
formed or the amount of substrate that has disappeared. Also is it possible in optically
clear solutions to monitor spechophotometrically the amount of product formed. This is
of particular interest because the first derivative of that curve will represent he course
of thrombin generation in the sample-
The following reactions further illustrate the present method:
Trigger
1. Clotting factors(V - XII) -> Prothrombinase
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2 Prothrombin
3. Thrombin +
Prothrombinase
Thrombin
Antitfuombins -> Inactive complexes
Thrombin
4. Indicator Agent > Signal Molecule
Reactions 2 and 3 go to completion so that thrombin is only transitoryly present in the
reaction mixture. During its presence it partakes in reaction 4, so that the extent of the
conversion of the indicator agent reflects the time during which- and the amount with
which, thrombin has catalysed that reaction. It is essential that the indicator agent is not
exhausted before the thrombin has disappeared. The reaction velocity should be propor-
tional to the concentration of thrombin at any moment, i.e- the concentration of substrate
has to be several times higher than Km.
In a test set up according to this principle a variety of different triggers may be used:
thromboplastins of any origin for investigating the ETP of the extrinsic pathway, contact
activators etc.
In performing the assay a great variation of protein concentrations, incubation times,
coagulation triggers, reagent concentrations and temperafures may be used. These
parameters may be varied according to the special purpose that the determination of the
ETP may serve e.g. determination of low molecular weight heparins, monitoring of oral
anticoagulation, detection of hyper-coagulable states etc.
The end level of substrate conversion is not necessarily completely fixed under all
circumstances, because the complex of thrombin to a2-Macroglobulin has a persistant
amidol)rtic activity. It may therefore be necessary to measure the optical density at a fixed
moment after starting the reaction, or, if the reaction mixture is not optically clear, such
as with the use of whole blood, to stop the reaction with aquenching solution and subject
the reaction mixture to manipulations (such as centrifugation or precipitation) that allow
measurement of the amount of the signal molecule present. Any chemical that will stop
the action of thrombin on the thrombin substrate can in principle serve this purpose.
Benzamidine, hirudin and alphaNAPAP are obvious candidates'
The indicator agent can be any molecule capable of reacting with thrombin. In such
reaction products should be formed which produce a measurable signal. P-nitroaniline,
easily detectable fotometrically at 405 nm is an obvious choice but other indicator agents
ntay be used, such as those producing fluorescent or electrochemical signals.
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